High frequency of loss of expression and allelic deletion of the APC and MCC genes in human prostate cancer

X. Gao, A. Zacharek, David Grignon, H. Liu, W. Sakr, A. T. Porter, Y. Q. Chen, K. V. Honn

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Loss of heterozygosity (LOH) or allelic deletion at various loci has been reported in the majority of human tumors. The frequently deleted targets are believed to be tumor suppressor genes. Recent studies have identified the APC and MCC genes at 5q21, as putative tumor suppressor genes. The APC and MCC genes have been implicated in the development of familial adenomatous polyposis coli and cancers of the gastrointestinal tract, ovary, breast and lung. In the present study, we investigated a possible role of the APC and MCC genes in prostate cancer development. mRNA expression of the APC and MCC genes and LOH at the APC and MCC loci were determined in prostate cancer tissues from 28 patients and 5 human prostatic adenocarcinoma cell lines. Of the informative cases, the frequency of LOH at the APC and MCC loci was 63% (10/16) and 54% (7/13), respectively. Overall, 65% (15/23) of the informative cases showed LOH at the APC and/or MCC gene. All prostate cancer cell lines showed homozygosity at all APC and MCC polymorphic sites studied. Approximately half (57%) of the tumor tissues examined showed a decreased expression of APC and MCC mRNA. Our data suggest that the APC and MCC genes may be involved in the formation of human prostate cancer (HPC).

Original languageEnglish (US)
Pages (from-to)111-117
Number of pages7
JournalInternational Journal of Oncology
Volume6
Issue number1
StatePublished - 1995
Externally publishedYes

Fingerprint

MCC Genes
APC Genes
Loss of Heterozygosity
Prostatic Neoplasms
Tumor Suppressor Genes
Cell Line
Messenger RNA
Adenomatous Polyposis Coli
Gastrointestinal Neoplasms
Ovary
Neoplasms
Adenocarcinoma
Breast
Lung

Keywords

  • loss of heterozygosity
  • mRNA expression
  • polymerase chain reaction
  • prostatic carcinoma
  • tumor suppressor gene

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

High frequency of loss of expression and allelic deletion of the APC and MCC genes in human prostate cancer. / Gao, X.; Zacharek, A.; Grignon, David; Liu, H.; Sakr, W.; Porter, A. T.; Chen, Y. Q.; Honn, K. V.

In: International Journal of Oncology, Vol. 6, No. 1, 1995, p. 111-117.

Research output: Contribution to journalArticle

Gao, X, Zacharek, A, Grignon, D, Liu, H, Sakr, W, Porter, AT, Chen, YQ & Honn, KV 1995, 'High frequency of loss of expression and allelic deletion of the APC and MCC genes in human prostate cancer', International Journal of Oncology, vol. 6, no. 1, pp. 111-117.
Gao, X. ; Zacharek, A. ; Grignon, David ; Liu, H. ; Sakr, W. ; Porter, A. T. ; Chen, Y. Q. ; Honn, K. V. / High frequency of loss of expression and allelic deletion of the APC and MCC genes in human prostate cancer. In: International Journal of Oncology. 1995 ; Vol. 6, No. 1. pp. 111-117.
@article{ea53f840055140ddae02af583a74b577,
title = "High frequency of loss of expression and allelic deletion of the APC and MCC genes in human prostate cancer",
abstract = "Loss of heterozygosity (LOH) or allelic deletion at various loci has been reported in the majority of human tumors. The frequently deleted targets are believed to be tumor suppressor genes. Recent studies have identified the APC and MCC genes at 5q21, as putative tumor suppressor genes. The APC and MCC genes have been implicated in the development of familial adenomatous polyposis coli and cancers of the gastrointestinal tract, ovary, breast and lung. In the present study, we investigated a possible role of the APC and MCC genes in prostate cancer development. mRNA expression of the APC and MCC genes and LOH at the APC and MCC loci were determined in prostate cancer tissues from 28 patients and 5 human prostatic adenocarcinoma cell lines. Of the informative cases, the frequency of LOH at the APC and MCC loci was 63{\%} (10/16) and 54{\%} (7/13), respectively. Overall, 65{\%} (15/23) of the informative cases showed LOH at the APC and/or MCC gene. All prostate cancer cell lines showed homozygosity at all APC and MCC polymorphic sites studied. Approximately half (57{\%}) of the tumor tissues examined showed a decreased expression of APC and MCC mRNA. Our data suggest that the APC and MCC genes may be involved in the formation of human prostate cancer (HPC).",
keywords = "loss of heterozygosity, mRNA expression, polymerase chain reaction, prostatic carcinoma, tumor suppressor gene",
author = "X. Gao and A. Zacharek and David Grignon and H. Liu and W. Sakr and Porter, {A. T.} and Chen, {Y. Q.} and Honn, {K. V.}",
year = "1995",
language = "English (US)",
volume = "6",
pages = "111--117",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - High frequency of loss of expression and allelic deletion of the APC and MCC genes in human prostate cancer

AU - Gao, X.

AU - Zacharek, A.

AU - Grignon, David

AU - Liu, H.

AU - Sakr, W.

AU - Porter, A. T.

AU - Chen, Y. Q.

AU - Honn, K. V.

PY - 1995

Y1 - 1995

N2 - Loss of heterozygosity (LOH) or allelic deletion at various loci has been reported in the majority of human tumors. The frequently deleted targets are believed to be tumor suppressor genes. Recent studies have identified the APC and MCC genes at 5q21, as putative tumor suppressor genes. The APC and MCC genes have been implicated in the development of familial adenomatous polyposis coli and cancers of the gastrointestinal tract, ovary, breast and lung. In the present study, we investigated a possible role of the APC and MCC genes in prostate cancer development. mRNA expression of the APC and MCC genes and LOH at the APC and MCC loci were determined in prostate cancer tissues from 28 patients and 5 human prostatic adenocarcinoma cell lines. Of the informative cases, the frequency of LOH at the APC and MCC loci was 63% (10/16) and 54% (7/13), respectively. Overall, 65% (15/23) of the informative cases showed LOH at the APC and/or MCC gene. All prostate cancer cell lines showed homozygosity at all APC and MCC polymorphic sites studied. Approximately half (57%) of the tumor tissues examined showed a decreased expression of APC and MCC mRNA. Our data suggest that the APC and MCC genes may be involved in the formation of human prostate cancer (HPC).

AB - Loss of heterozygosity (LOH) or allelic deletion at various loci has been reported in the majority of human tumors. The frequently deleted targets are believed to be tumor suppressor genes. Recent studies have identified the APC and MCC genes at 5q21, as putative tumor suppressor genes. The APC and MCC genes have been implicated in the development of familial adenomatous polyposis coli and cancers of the gastrointestinal tract, ovary, breast and lung. In the present study, we investigated a possible role of the APC and MCC genes in prostate cancer development. mRNA expression of the APC and MCC genes and LOH at the APC and MCC loci were determined in prostate cancer tissues from 28 patients and 5 human prostatic adenocarcinoma cell lines. Of the informative cases, the frequency of LOH at the APC and MCC loci was 63% (10/16) and 54% (7/13), respectively. Overall, 65% (15/23) of the informative cases showed LOH at the APC and/or MCC gene. All prostate cancer cell lines showed homozygosity at all APC and MCC polymorphic sites studied. Approximately half (57%) of the tumor tissues examined showed a decreased expression of APC and MCC mRNA. Our data suggest that the APC and MCC genes may be involved in the formation of human prostate cancer (HPC).

KW - loss of heterozygosity

KW - mRNA expression

KW - polymerase chain reaction

KW - prostatic carcinoma

KW - tumor suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=0028917774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028917774&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 111

EP - 117

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -